In a double-blind comparative trial, 100 men with uncomplicated gonorrhea caused by i8-lactamase-negative Neisseria gonorrhoeae were treated with a single 0.25-g dose of ciprofloxacin administered orally or with 3.5 g of ampicillin plus 1.0 g of probenecid administered orally. Urethral infection was eradicated in all 49 men treated with ciprofloxacin and in 47 (92%) of 51 men treated with ampicillin-probenecid (P = 0.12). The geometric mean MICs for pretreatment isolates were 0.008 ,ug of ciprofloxacin per ml, 0.09 ,Ig of penicillin G per ml, 0.52 ,ug of tetracycline per ml, and 23.5 ,ug of spectinomycin per ml. Chiamydia trachomatis infection persisted in 10 of 11 men treated with ciprofloxacin and in 11 of 14 men treated with ampicillin-probenecid. A single 0.25-g dose of ciprofloxacin was effective for treatment of uncomplicated urethral gonorrhea in men, but it did not eradicate coinfection with C. trachomatis.
The increasing prevalence of P-lactamase-producing strains of Neisseria gonorrhoeae (11, 16) and strains with chromosomally mediated resistance to the penicillins or tetracycline (2, 3, 7, 13) continues to stimulate research into new regimens for gonorrhea therapy. In addition, each of the currently recommended (4) regimens has limitations, including reduced efficacy for infection of the rectum or pharynx, toxicity, reduced patient acceptability of parenteral therapy, cost, or lack of efficacy for concomitant infections.
Ciprofloxacin hydrochloride is a new quinolone carboxylic acid derivative with excellent bactericidal activity against gram-negative bacteria (1, 5, 6) . High levels in serum, good penetration into body fluids, and a half-life in serum of approximately 4 h (8, 9) suggest that a single oral dose of 0.25 g may be effective therapy for uncomplicated gonorrhea. This study was undertaken to compare the efficacy of therapy with 0.25 g of ciprofloxicin orally with that of 3.5 g of ampicillin plus 1.0 g of probenecid orally in men with uncomplicated gonococcal urethritis.
(These data were presented in part at the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy [Program Abstr. 25th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 265, 1985] .)
MATERIALS AND METHODS
Patient population. Men aged .16 years attending a sexually transmitted disease clinic were invited to participate in the study if a Gram-stained smear of urethral exudate showed polymorphonuclear leukocytes containing gramnegative intracellular diplococci or if they had untreated, culture-documented gonorrhea. Men with a history of allergy to penicillin or carboxyquinolones or renal impairment, those who had received antibiotic therapy within the preceding 2 weeks, and those with signs or symptoms of epididymitis or disseminated gonococcal infection were excluded from the study. The sexual orientation of the patients was classified on the basis of their sexual contacts during the preceding 2 months. (18) .
Antimicrobial susceptibility testing. Isolates of N. gonorrhoeae were frozen at -70°C in a 1:1 mixture of tryptic soy-yeast broth and horse serum for later antimicrobial susceptibility testing. ,-Lactamase production was tested by the acidometric method (19) . The MICs of ciprofloxacin, penicillin G, tetracycline hydrochloride, and spectinomycin were determined by the agar-dilution technique with gonococcal agar base (Difco Laboratories, Detroit, Mich.) containing 1% hemoglobin, 1% IsoVitaleX (BBL Microbiology Systems, Cockeysville, Md.), and various concentrations of antibiotic (20) .
Treatment and study design. The study was double blind, with each patient receiving nine capsules and one tablet. For the group receiving ciprofloxacin, the capsules contained lactose placebo and the tablet contained 0.25 g of ciprofloxacin; the group treated with ampicillin-probenecid received nine capsules containing these drugs and a placebo tablet. Patients took their assigned medications in single dose while in the clinic and were instructed to abstain from sexual contact until they returned for follow-up 5 to 10 days later. At the follow-up visit, repeat urethral cultures for N. gonorrhoeae and C. trachomatis were obtained from appropriate sites. Total and differential leukocyte count, hemoglobin, hematocrit, urinalysis, and assays of serum creatinine, ANTIMICROB. AGENTS CHEMOTHER. 
RESULTS
Study population. One hundred six subjects were enrolled in the study. One of these was subsequently excluded because N. gonorrhoeae was not isolated at the initial visit, four failed to return for the follow-up visit, and one was unable to swallow the medication, leaving 100 evaluable subjects. The excluded subjects were similar in age, sexual orientation, and other demographic characteristics to the remainder of the subjects (data not shown). A total of 49 evaluable patients were treated with ciprofloxacin and 51 received ampicillin-probenecid. These two groups were similar in demographic characteristics and sexual orientation ( Table 1) .
Eradication of N. gonorrhoeae. In Table 2 are shown the results for patients with urethral and rectal gonorrhea. Ciprofloxacin cured 49 of 49 urethral infections and ampicillin-probenecid cured 47 (92%) of 51 urethral infections (P = 0.12). Two of the four ampicillin-probenecid recipients with persistent gonorrhea admitted to sexual contact with untreated partners before the follow-up visit. Ciprofloxacin cured four of five rectal infections and eradicated the single pharyngeal infection in that group, whereas ampicillinprobenecid eradicated a single rectal infection and one of six pharyngeal infections.
Effect of treatment on chlamydial infection. C. trachomatis was isolated prior to treatment from the urethras of 15 subjects and from the rectums of 3 subjects; overall, C. trachomatis was isolated from 8 (16%) of 49 subjects treated with ciprofloxacin and 10 (20%) of 51 treated subjects with ampicillin-probenecid. C. trachomatis persisted in seven patients in each treatment group. In addition, C. trachomatis was first isolated at the follow-up visit from the urethras of three ciprofloxacin-treated patients and four patients who received ampicillin-probenecid, all of whom denied sexual contact after treatment. Thus, 10 (91%) of 11 presumptive or proven chlamydial infections persisted after treatment with ciprofloxacin, as did 11 (79%) of 14 after treatment with ampicillin-probenecid. Toxicity and tolerance. Both ciprofloxacin and ampicillinprobenecid were well tolerated. No gastrointestinal problems or symptoms referable to the central nervous system were reported. One patient who received ampicillinprobenecid developed a pruritic rash and facial edema that responded to treatment with diphenhydramine. Two subjects treated with ciprofloxacin and two subjects treated with ampicillin-probenecid had mild unexplained increases of aspartate aminotransferase or alkaline phosphatase, without symptoms and without changes in bilirubin level.
Antimicrobial susceptibility of N. gonorrhoeae. Of 100 pretreatment isolates, 77 were available for antimicrobial susceptibility testing; the remainder failed to survive storage, transport, or the testing procedure. No isolate produced 3-lactamase. The results (Table 3) were within the expected ranges for penicillin, tetracycline, and spectinomycin (10, 15) . The ciprofloxacin MIC was 0.008 ,ug/ml for 71 (92%) of 77 isolates. Five isolates were inhibited by 0.015 ,ug and one was inhibited by 0.03 pug of ciprofloxacin per ml.
DISCUSSION
Ciprofloxacin in a single oral dose of 0.25 g cured 100% and 3.5 g of ampicillin plus 1.0 g of probenecid administered orally cured 92% of volunteers with uncomplicated gonococcal urethritis. The efficacy of ciprofloxacin, therefore, compares favorably with that of other regimens for gonococcal urethritis, including those that require parenteral administration. Although no infections caused by P-lactamaseproducing gonococci were treated in this study, ciprofloxacin has excellent activity against such strains (1) . The recent development and spread of gonococci with chromosomally mediated resistance to penicillin (7) and tetracycline (3, 7) emphasize the need for effective alternatives to regimens with these antibiotics.
Too few rectal and pharyngeal infections were treated to permit meaningful analysis. However, the failure of ciprofloxacin to eradicate one of five rectal infections suggests that caution should be exercised in extrapolating the efficacy of ciprofloxacin against urethral infection to other anatomic sites. The poor efficacy of ampicillin-probenecid against pharyngeal gonorrhea was expected (14) .
The in vitro susceptibilities of N. gonorrhoeae to ciprofloxacin, penicillin G, tetracycline, and spectinomycin (12) , coexisting chlamydial infections were not eradicated, as is the case for all other single-dose gonorrhea treatment regimens that have been studied. Failure to eradicate chlamydial infections is associated with postgonococcal urethritis in men and fosters continued transmission of C. trachomatis. Moreover, treatment of gonorrhea in women with regimens that do not eradicate cervical chlamydial infection results in a 30% risk of nongonococcal pelvic inflammatory disease in the succeeding 6 weeks (17) .
No significant drug toxicity or problems with tolerance were observed with either regimen. The ease of taking a single small tablet and the avoidance of an intramuscular injection represent conveniences for the ciprofloxacin regimen.
In summary, a single oral dose of 0.25 g of ciprofloxacin equals or exceeds the efficacy, tolerance, and safety of ampicillin-probenecid in the treatment of urethral gonorrhea in men, but patients at risk for coexisting infection with C. trachomatis should also be treated with a 7-day course of a tetracycline. Additional data are needed on the efficacy of ciprofloxacin for rectal and pharyngeal gonococcal infections in men and for gonorrhea in women.
